Today: 28 February 2026
Subscribe
Browse Category

NASDAQ:SPRB 6 October 2025 - 19 October 2025

Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough News – Experts Weigh In

Spruce Biosciences shares soared over 1,300% on October 6 after its lead drug for Sanfilippo Syndrome Type B received FDA Breakthrough Therapy status. The company raised $50 million in a private placement at $68 per share. SPRB traded in the mid-$150s on October 19, up from $8 before the announcement. Analyst opinions remain split, with a consensus price target below current levels.
19 October 2025
·
Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Spruce Biosciences shares soared over 1,300% after the FDA granted breakthrough therapy designation to its lead drug for Sanfilippo Syndrome Type B. Trading was repeatedly halted amid a flood of investor interest, including public backing from Martin Shkreli. The company, recently relisted on Nasdaq, faces ongoing financial strain with just $16.4 million in cash and no significant revenue.
7 October 2025
··
Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences shares jumped over 250% intraday on Oct. 6, 2025, after the FDA granted Breakthrough Therapy Designation to its lead drug, tralesinidase alfa, for Sanfilippo Syndrome Type B. The stock rose from around $9 to $31. Spruce regained its Nasdaq listing in September following a reverse split. The company reported $16.4 million in cash as of June 30 and remains unprofitable.
6 October 2025
··
Go toTop